000166511 001__ 166511
000166511 005__ 20240229123230.0
000166511 0247_ $$2doi$$a10.3389/fphar.2020.549804
000166511 0247_ $$2pmid$$apmid:33328982
000166511 0247_ $$2pmc$$apmc:PMC7734336
000166511 037__ $$aDKFZ-2020-02954
000166511 041__ $$aeng
000166511 082__ $$a610
000166511 1001_ $$0P:(DE-HGF)0$$aSagini, Micah N$$b0$$eFirst author
000166511 245__ $$aRiproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma.
000166511 260__ $$aLausanne$$bFrontiers Media$$c2020
000166511 3367_ $$2DRIVER$$aarticle
000166511 3367_ $$2DataCite$$aOutput Types/Journal article
000166511 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609333776_7149
000166511 3367_ $$2BibTeX$$aARTICLE
000166511 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166511 3367_ $$00$$2EndNote$$aJournal Article
000166511 500__ $$a#EA:G401#LA:G401#
000166511 520__ $$aRiproximin (Rpx) is a type II ribosome-inactivating protein with specific anti-proliferative activity. It was purified from Ximenia americana by affinity chromatography using a resin coupled with lactosyl residues. The same technique facilitated isolation of proteins with lectin-like properties from human Suit2-007 and rat ASML pancreatic cancer cells, which were termed lactosyl-sepharose binding proteins (LSBPs). The role of these proteins in cancer progression was investigated at mRNA level using chip array data of Suit2-007 and ASML cells re-isolated from nude rats. These data compared significant mRNA expression changes when relating primary (pancreas) and metastatic (liver) sites following orthotopic and intraportal implantation of Pancreatic Ductal Adenocarcinoma (PDAC) cells, respectively. The affinity of Rpx to 13 simple sugar structures was modeled by docking experiments, the ranking of which was principally confirmed by NMR-spectroscopy. In addition, Rpx and LSBPs were evaluated for anti-proliferative activity and their cellular uptake was assessed by fluorescence microscopy. From 13 monosaccharides evaluated, open-chain rhamnose, β-d-galactose, and α-l-galactopyranose showed the highest affinities for site 1 of Rpx's B-chain. NMR evaluation yielded a similar ranking, as galactose was among the best binders. Both, Rpx and LSBPs reduced cell proliferation in vitro, but their anti-proliferative effects were decreased by 15-20% in the presence of galactose. The program 'Ingenuity Pathway Analysis' identified 2,415 genes showing significantly modulated mRNA expression following exposure of Suit2-007 cells to Rpx in vitro. These genes were then matched to those 1,639 genes, which were significantly modulated in the rat model when comparing primary and metastatic growth of Suit2-007 cells. In this overlap analysis, LSBP genes were considered separately. The potential suitability of Rpx for treating metastatic Suit2-007 PDAC cells was reflected by those genes, which were modulated by Rpx in a way opposite to that observed in cancer progression. Remarkably, these were 14% of all genes modulated during cancer progression, but 71% of the respective LSBP gene subgroup. Based on these findings, we predict that Rpx has the potential to treat PDAC metastasis by modulating genes involved in metastatic progression, especially by targeting LSBPs.
000166511 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000166511 588__ $$aDataset connected to CrossRef, PubMed,
000166511 650_7 $$2Other$$aPancreatic ductal adenocarcinoma
000166511 650_7 $$2Other$$aaffinity 
000166511 650_7 $$2Other$$acellular lectins
000166511 650_7 $$2Other$$alactosyl-sepharose binding proteins
000166511 650_7 $$2Other$$amonosaccharides
000166511 650_7 $$2Other$$aribosome-inactivating protein
000166511 7001_ $$0P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aKlika, Karel D$$b1$$udkfz
000166511 7001_ $$aOrry, Andrew$$b2
000166511 7001_ $$0P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aZepp, Michael$$b3$$udkfz
000166511 7001_ $$0P:(DE-He78)2b46863912e593214959beb6e2de281c$$aMutiso, Joshua$$b4
000166511 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b5$$eLast author$$udkfz
000166511 773__ $$0PERI:(DE-600)2587355-6$$a10.3389/fphar.2020.549804$$gVol. 11, p. 549804$$p549804$$tFrontiers in pharmacology$$v11$$x1663-9812$$y2020
000166511 909CO $$ooai:inrepo02.dkfz.de:166511$$pVDB
000166511 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166511 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000166511 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166511 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2b46863912e593214959beb6e2de281c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166511 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166511 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000166511 9141_ $$y2020
000166511 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PHARMACOL : 2018$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-08-20
000166511 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-20
000166511 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-20
000166511 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lMolekulare Toxikologie und Chemotherapie$$x0
000166511 980__ $$ajournal
000166511 980__ $$aVDB
000166511 980__ $$aI:(DE-He78)G401-20160331
000166511 980__ $$aUNRESTRICTED